Literature DB >> 22635524

Intensification of antibiotic use within acute care hospitals in the Netherlands.

H M Kwint1, P D van der Linden, M M B Roukens, S Natsch.   

Abstract

OBJECTIVES: To report and analyse trends in antibiotic use in Dutch university hospitals, large teaching hospitals and general hospitals over the period 2003 to 2009.
METHODS: Data on the use of antibiotics and hospital resource indicators were obtained by distributing a questionnaire to all Dutch hospital pharmacies. Antibiotic use was expressed as the number of defined daily doses (DDDs) per 100 patient-days, per 100 admissions and per 1000 inhabitants per day. The latter was achieved by extrapolating sample data by means of imputation and up-scaling.
RESULTS: From 2003 to 2009, the mean length of hospital stay decreased from 6.27 to 4.50 days (-28%). Total systemic antibiotic use significantly increased from 52.3 to 69.8 DDDs per 100 patient-days (P < 0.001). Despite the overall constant use when expressed in DDDs per 100 admissions, we found a significant increase in the total use of piperacillin/tazobactam, cefazolin, ceftriaxone, meropenem, azithromycin, gentamicin, ciprofloxacin and vancomycin. Mean total systemic use expressed in DDDs per 1000 inhabitants per day gradually increased by 38% from 0.73 in 2003 to 1.01 in 2009.
CONCLUSIONS: Total hospital antibiotic consumption is still low in the Netherlands compared with other European countries. Also, between 2003 and 2009 the use of antibiotics in individual hospitalized patients remained stable. However, since they remained in the hospital for a shorter period of time, the number of DDDs per 100 patient-days increased. This results in an intensification of antibiotic treatment per hospital bed, leading to a possible increase in selection pressure towards resistance. This may create a problem for future patients. To limit the emergence and transmission of antimicrobial-resistant bacteria, effective antibiotic stewardship is essential.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22635524     DOI: 10.1093/jac/dks190

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Selection of hospital antimicrobial prescribing quality indicators: a consensus among German antibiotic stewardship (ABS) networkers.

Authors:  J Thern; K de With; R Strauss; M Steib-Bauert; N Weber; W V Kern
Journal:  Infection       Date:  2013-12-11       Impact factor: 3.553

2.  Antibiotic hospital consumption expressed in defined daily doses (DDD)/100 bed-days.

Authors:  M Cizman; B Beovic
Journal:  Infection       Date:  2014-02       Impact factor: 3.553

Review 3.  A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Anne F Voor In 't Holt; Juliëtte A Severin; Emmanuel M E H Lesaffre; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

Review 4.  Antimicrobial Stewardship Programs: Appropriate Measures and Metrics to Study their Impact.

Authors:  Andrew M Morris
Journal:  Curr Treat Options Infect Dis       Date:  2014

5.  Impact of changes in the WHO's 2019 update of DDDs on the measurement of adult hospital antibacterial consumption in Catalonia (Spain), 2008-18.

Authors:  Santiago Grau; Sergi Hernández; Enric Limón; Esther Calbo; Juan P Horcajada
Journal:  JAC Antimicrob Resist       Date:  2020-10-16

6.  Extensive antibiotic prescription rate among hospitalized patients in Uganda: but with frequent missed-dose days.

Authors:  Ronald Kiguba; Charles Karamagi; Sheila M Bird
Journal:  J Antimicrob Chemother       Date:  2016-03-05       Impact factor: 5.790

7.  Consumption of antibiotics in Chinese public general tertiary hospitals (2011-2014): Trends, pattern changes and regional differences.

Authors:  Xiaoyuan Qu; Chang Yin; Xihong Sun; Shusheng Huang; Chaofan Li; Panpan Dong; Xiufang Lu; Zhuo Zhang; Aitian Yin
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.